Therapy and symptoms before and after venous sinus stent placementa
| Before Venous Sinus Stent Placement | After Venous Sinus Stent Placement | ||||
|---|---|---|---|---|---|
| Data Available (%) (No.) | Data Available (%) (No.) | ||||
| Headache intensity (VAS) | 84.6% (11/13) | 7 (5.5–9.0) | Headache intensity (VAS) | 84.6% (11/13) | 0 (0–0) |
| Headache intensity improvement (VAS) | 84.6% (11/13) | −7 (−9 to −4.5) | |||
| Headache, frequency (per wk) | 84.6% (11/13) | 7 (4.5–7) | Headache frequency (per wk) | 84.6% (11/13) | 0 (0–0) |
| ≤1 | 15.4% (2) | ≤1 | 84.6% (11) | ||
| 2–4 | 0.0% (0/0) | 2–4 | 0.0% (0) | ||
| >4 | 69.2% (9) | >4 | 0.0% (0) | ||
| Patients with >1 type of headache | 84.6% (11/13) | 46.2% (6) | Headache frequency improvement (per wk) | 84.6% (11/13) | −7 (−7 to −4.5) |
| Nausea/emesis | 100% (13/13) | 61.5% (8) | Nausea/emesis IMP-AF | 100% (8/8) | 100% (8) |
| Photophobia/phonophobia | 100% (13/13) | 23.1% (3) | Photophobia/phonophobia IMP-AF | 100% (3/3) | 100% (3) |
| Tinnitus | 100% (13/13) | 61.5% (8) | Tinnitus IMP-AF | 100% (8/8) | 75.0% (6) |
| Diplopia | 100% (13/13) | 23.1% (3) | Diplopia IMP-AF | 100% (3/3) | 100% (3) |
| Visual disturbances | 100% (13/13) | 69.2% (9) | Visual disturbances IMP-AF | 100% (9/9) | 88.9% (8) |
| Papilledema | 100% (13/13) | 69.2% (9) | Papilledema IMP-AF | 88.9% (8/9) | 88.9% (8) |
| Daily life impairment | 84.6% (11/13) | 84.6% (11) | Daily life quality IMP-AF | 100% (11/11) | 100% (11/11) |
| Symptom duration (mo) | 100% (15/15) | 23.6 (7.3–52.1) | Follow-up period (mo) | 100% (13/13) | 16.6 (7.8–32.2) |
| Other therapy | |||||
| Conservative therapy | 100% (13/13) | 92.3% (12) | |||
| Duration of conservative therapy (in months) | 100% (15/15) | 18.9 (6–26) | |||
| Surgical therapy | 100% (15/15) | 7.7% (1) | |||
Note:—HA indicates headache; IMP-AF, improvement among affected.
↵a Data are expressed as percentages (No.) or median (interquartile range [25%–75%]).